Clinical Trial Update: T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes for Epstein-Barr virus-positive nasopharyngeal carcinoma; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED